Serevent “Manipulated” Data Shows Need For Transparency – Public Citizen
Executive Summary
GlaxoSmithKline's handling of Serevent risk data from the SMART study demonstrates the need for greater transparency in the FDA review process, Public Citizen's Health Research Group suggests in a letter to The Lancet